PhD, DABCC, NRCC, SC (ASCP)CM
Dr. Muluhngwi's recent research activities include thestudy of a circulating biomarker for CNS tumors and a retrospective study of oncogenic driver mutations in non-small-cell lung cancer patients. He hopes his interest in HLA and transplantation, which stems from his experience as a laboratory technician, will lead to improving patient care through high-quality laboratory testing and interpretation.
Sharp C.N., Fletcher A.,Muluhngwi P., Snyder J., Linder M. W., and Jortani S. A.A shared diagnostic stewardship approach toward improving autoimmune encephalopathy send-out testing utilization. J Appl Lab Med.24 Nov 2020 (https://doi.org/10.1093/jalm/jfaa123)
Muluhngwi P., Valdes, Jr. R., Fernandez-Botran R., Burton E., Williams B., Linder M. W. (2019)Cell-free DNA diagnostics: current and prospective applications in oncology. Pharmacogenomics. 20(5):357-380.
Muluhngwi P., Sharp C.N., Pozzi N., Elin R., Jortani S. A.Verification of newly FDA- approved kappa and lambda free light chain assays on a previously untested platform. J Appl Lab Med.2019;4(3):323-330.
AddressPhillips Wangensteen Building
515 Delaware St SE
Minneapolis, MN 55455